FAP, April 23 / PRNewswire-Asianet /-- recently, the company's clinical trial application for toluenesulfonate ZG2001 tablets has been approved by the US Food and Drug Administration ("FDA") for the treatment of advanced solid tumors with KRAS mutations, according to the company's announcement. In addition, the company recently received a "Drug Clinical trial approval notice" approved by the State Drug Administration, and the clinical trial of ZGGS15 for injection in the treatment of patients with advanced solid tumor was approved.